CL2018000955A1 - Terapia de combinación para el tratamiento de neoplasias malignas - Google Patents
Terapia de combinación para el tratamiento de neoplasias malignasInfo
- Publication number
- CL2018000955A1 CL2018000955A1 CL2018000955A CL2018000955A CL2018000955A1 CL 2018000955 A1 CL2018000955 A1 CL 2018000955A1 CL 2018000955 A CL2018000955 A CL 2018000955A CL 2018000955 A CL2018000955 A CL 2018000955A CL 2018000955 A1 CL2018000955 A1 CL 2018000955A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- combination therapy
- malignant neoplasms
- combination
- idh2
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 abstract 2
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242218P | 2015-10-15 | 2015-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018000955A1 true CL2018000955A1 (es) | 2018-09-14 |
Family
ID=57219007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000955A CL2018000955A1 (es) | 2015-10-15 | 2018-04-13 | Terapia de combinación para el tratamiento de neoplasias malignas |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10695352B2 (enExample) |
| EP (1) | EP3362070B1 (enExample) |
| JP (1) | JP6895956B2 (enExample) |
| KR (1) | KR102701893B1 (enExample) |
| CN (1) | CN108601787B (enExample) |
| AU (1) | AU2016340098B2 (enExample) |
| BR (1) | BR112018007447B1 (enExample) |
| CA (1) | CA3002029A1 (enExample) |
| CL (1) | CL2018000955A1 (enExample) |
| EA (1) | EA036129B1 (enExample) |
| ES (1) | ES2862730T3 (enExample) |
| IL (1) | IL258580B (enExample) |
| MX (1) | MX381582B (enExample) |
| SG (2) | SG11201802964QA (enExample) |
| WO (1) | WO2017066611A1 (enExample) |
| ZA (1) | ZA201802420B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10206601B2 (en) | 2013-12-09 | 2019-02-19 | Medtronic, Inc. | Noninvasive cardiac therapy evaluation |
| PH12021551647A1 (en) | 2014-03-14 | 2022-06-06 | Agios Pharmaceuticals Inc | Pharmaceutical compositions of therapeutically active compounds |
| HUE067449T2 (hu) | 2015-10-15 | 2024-10-28 | Servier Lab | Ivozidenib, citarabin és daunorubicin vagy idarubicin kombinációs terápa akut mielogén leukémia kezelésére |
| MD3362066T2 (ro) * | 2015-10-15 | 2022-08-31 | Les Laboratoires Servier Sas | Terapie combinată pentru tratamentul tumorilor maligne |
| JP2018534288A (ja) | 2015-10-15 | 2018-11-22 | アジオス ファーマシューティカルズ， インコーポレイテッド | 悪性腫瘍の治療のための併用療法 |
| US11219769B2 (en) | 2016-02-26 | 2022-01-11 | Medtronic, Inc. | Noninvasive methods and systems of determining the extent of tissue capture from cardiac pacing |
| KR102498693B1 (ko) | 2016-09-07 | 2023-02-10 | 셀진 코포레이션 | 정제 조성물 |
| WO2018204787A1 (en) | 2017-05-05 | 2018-11-08 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
| CN119280245A (zh) * | 2017-06-12 | 2025-01-10 | 法国施维雅药厂 | 使用组合疗法治疗脑肿瘤的方法 |
| IL271946B (en) * | 2017-07-09 | 2022-09-01 | Biosight Ltd | Combination cancer therapy |
| WO2019191602A1 (en) | 2018-03-29 | 2019-10-03 | Medtronic, Inc. | Left ventricular assist device adjustment and evaluation |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092915A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| WO2020092906A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| US11697025B2 (en) | 2019-03-29 | 2023-07-11 | Medtronic, Inc. | Cardiac conduction system capture |
| JP7585231B2 (ja) * | 2019-04-29 | 2024-11-18 | イミュノジェン， インコーポレイテッド | 抗ｃｄ１２３免疫複合体を含む治療的組み合わせ |
| WO2020257671A1 (en) | 2019-06-20 | 2020-12-24 | Celgene Corporation | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
| US11497431B2 (en) | 2019-10-09 | 2022-11-15 | Medtronic, Inc. | Systems and methods for configuring cardiac therapy |
| US12201843B2 (en) | 2019-10-09 | 2025-01-21 | Medtronic, Inc. | Synchronizing external electrical activity |
| US20220401450A1 (en) | 2019-11-14 | 2022-12-22 | Celgene Corporation | Pediatric formulations for treatment of cancer |
| CN111087408B (zh) * | 2020-01-03 | 2021-04-02 | 浙江大学 | 一种大环结构的idh2突变体抑制剂及其医药用途 |
| WO2022192621A1 (en) * | 2021-03-12 | 2022-09-15 | Celgene Corporation | Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| ATE302597T1 (de) | 1997-06-06 | 2005-09-15 | Depomed Inc | Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung |
| MXPA02007254A (es) | 2000-02-04 | 2002-12-09 | Depomed Inc | Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero. |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| US7038038B2 (en) * | 2003-03-17 | 2006-05-02 | Pharmion Corporation | Synthesis of 5-azacytidine |
| US7192781B2 (en) | 2004-04-13 | 2007-03-20 | Pharmion Corporation | Methods for stabilizing 5-azacytidine in plasma |
| DK3782612T3 (da) * | 2008-05-15 | 2024-01-15 | Celgene Corp | Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf |
| PL2307002T3 (pl) * | 2008-06-09 | 2013-05-31 | Cyclacel Ltd | Kombinacje sapacytabiny lub cndac z inhibitorami metylotransferazy dna, takimi jak decytabina i prokaina |
| CN102985557B (zh) | 2009-03-13 | 2018-06-15 | 安吉奥斯医药品有限公司 | 用于细胞增殖相关病症的方法和组合物 |
| EP2525790B1 (en) * | 2009-10-21 | 2020-05-27 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| PL2773360T3 (pl) * | 2011-11-03 | 2018-09-28 | Millennium Pharmaceuticals, Inc. | Podawanie inhibitora enzymu aktywującego NEDD8 i środka hipometylującego |
| SMT201800334T1 (it) | 2012-01-06 | 2018-09-13 | Agios Pharmaceuticals Inc | Composti terapeuticamente attivi e loro metodi di utilizzo |
| MX375030B (es) * | 2013-07-11 | 2025-03-06 | Agios Pharmaceuticals Inc | Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer. |
| CN105916507A (zh) | 2013-08-02 | 2016-08-31 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| WO2015018060A1 (en) | 2013-08-09 | 2015-02-12 | Agios Pharmaceuticals, Inc. | Crystalline forms of therapeutically active compounds and use thereof |
| AU2015324158A1 (en) | 2014-09-29 | 2017-04-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3253746A1 (en) | 2015-02-04 | 2017-12-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN108349933A (zh) | 2015-08-05 | 2018-07-31 | 安吉奥斯医药品有限公司 | 制备6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二醇和6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二胺的方法 |
| JP2018534288A (ja) | 2015-10-15 | 2018-11-22 | アジオス ファーマシューティカルズ， インコーポレイテッド | 悪性腫瘍の治療のための併用療法 |
| MA43374A (fr) | 2015-12-04 | 2018-10-10 | Agios Pharmaceuticals Inc | Méthodes de traitement de tumeurs malignes |
| CA3015753A1 (en) | 2016-02-26 | 2017-08-31 | Celgene Corporation | Idh2 inhibitors for the treatment of haematological maligancies and solid tumours |
-
2016
- 2016-10-14 CA CA3002029A patent/CA3002029A1/en not_active Abandoned
- 2016-10-14 BR BR112018007447-0A patent/BR112018007447B1/pt active IP Right Grant
- 2016-10-14 AU AU2016340098A patent/AU2016340098B2/en active Active
- 2016-10-14 EA EA201890961A patent/EA036129B1/ru not_active IP Right Cessation
- 2016-10-14 JP JP2018519352A patent/JP6895956B2/ja active Active
- 2016-10-14 WO PCT/US2016/057102 patent/WO2017066611A1/en not_active Ceased
- 2016-10-14 US US15/768,462 patent/US10695352B2/en active Active
- 2016-10-14 SG SG11201802964QA patent/SG11201802964QA/en unknown
- 2016-10-14 ES ES16788866T patent/ES2862730T3/es active Active
- 2016-10-14 SG SG10201912869WA patent/SG10201912869WA/en unknown
- 2016-10-14 KR KR1020187013741A patent/KR102701893B1/ko active Active
- 2016-10-14 MX MX2018004599A patent/MX381582B/es unknown
- 2016-10-14 CN CN201680072973.3A patent/CN108601787B/zh active Active
- 2016-10-14 EP EP16788866.8A patent/EP3362070B1/en active Active
-
2018
- 2018-04-09 IL IL258580A patent/IL258580B/en active IP Right Grant
- 2018-04-12 ZA ZA2018/02420A patent/ZA201802420B/en unknown
- 2018-04-13 CL CL2018000955A patent/CL2018000955A1/es unknown
-
2020
- 2020-05-21 US US16/880,871 patent/US20210100805A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201802420B (en) | 2020-08-26 |
| MX2018004599A (es) | 2018-09-21 |
| IL258580A (en) | 2018-05-31 |
| SG10201912869WA (en) | 2020-02-27 |
| CN108601787B (zh) | 2022-07-29 |
| KR20180064529A (ko) | 2018-06-14 |
| NZ741433A (en) | 2024-07-26 |
| MX381582B (es) | 2025-03-12 |
| BR112018007447A2 (en) | 2018-10-23 |
| SG11201802964QA (en) | 2018-05-30 |
| AU2016340098A1 (en) | 2018-05-10 |
| KR102701893B1 (ko) | 2024-09-03 |
| EA036129B1 (ru) | 2020-10-01 |
| US20180303840A1 (en) | 2018-10-25 |
| CA3002029A1 (en) | 2017-04-20 |
| EA201890961A1 (ru) | 2018-11-30 |
| JP6895956B2 (ja) | 2021-06-30 |
| WO2017066611A1 (en) | 2017-04-20 |
| US10695352B2 (en) | 2020-06-30 |
| EP3362070B1 (en) | 2021-01-27 |
| BR112018007447B1 (pt) | 2023-12-05 |
| JP2018535951A (ja) | 2018-12-06 |
| ES2862730T3 (es) | 2021-10-07 |
| US20210100805A1 (en) | 2021-04-08 |
| CN108601787A (zh) | 2018-09-28 |
| EP3362070A1 (en) | 2018-08-22 |
| IL258580B (en) | 2021-05-31 |
| AU2016340098B2 (en) | 2022-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018004599A (es) | Terapia de combinacion para el tratamiento de neoplasias malignas. | |
| CL2018000943A1 (es) | Terapia de combinación para tratar tumores malignos | |
| MX2018010261A (es) | Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
| MX2018006831A (es) | Metodos de tratamiento de neoplasias malignas. | |
| CL2018000927A1 (es) | Terapia combinada para el tratamiento de neoplasias malignas | |
| MX2018004587A (es) | Terapia de combinacion para tratar tumores malignos. | |
| UY36307A (es) | Terapias combinadas para el tratamiento del cáncer | |
| MX2024000253A (es) | Inhibicion del smarca2 para el tratamiento del cancer. | |
| MX373045B (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| MA40437A (fr) | Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux | |
| CL2015002807A1 (es) | Terapia de combinación | |
| EA201691866A1 (ru) | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии | |
| TW201611847A (en) | Compounds and compositions for treating EGFR expressing tumors | |
| MX2017016868A (es) | Composiciones y metods para inhibir actividad de arginasa. | |
| MX2017010595A (es) | Métodos, composiciones, y equipos para tratamiento de cáncer. | |
| MX2018012508A (es) | Combinaciones para el tratamiento de neoplasias utilizando localizacion de celulas quiescentes e inhibidores de la mitosis. | |
| MX2023000549A (es) | Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr. | |
| MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
| MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
| MX2016015161A (es) | Metodos de tratamiento de cancer de mama luminal a positivo para pr con inhibidor de pi3k, pictilisib. | |
| MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
| MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. | |
| PH12016501838A1 (en) | Compounds and their methods of use | |
| EA201691846A1 (ru) | Композиции и способы лечения рака печени | |
| EA201890956A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей |